Impetigo News and Research

RSS

Impetigo (sometimes impetaigo) is a superficial bacterial skin infection most common among pre-school children. People who play close contact sports such as rugby, American football and wrestling are also susceptible, regardless of age. Impetigo is not as common in adults. It is also highly contagious. The name derives from the Latin ''impetere'' ("assail"). It is also known as school sores.

AI model empowers atopic dermatitis patients to detect complications from bacterial or viral infections

A team of dermatologists has developed an artificial intelligence (AI) model that empowers atopic dermatitis (AD) patients to detect complications from bacterial or viral infections and distinguish between eczema and skin lesions caused by a type of blood cancer.

14 Mar 2023

Study paves the way for efficient one-dose strategy to reduce scabies prevalence

One dose of an anti-parasite drug was just as effective as two at significantly reducing the spread of scabies, the contagious, intensely itchy skin condition, according to a new study.

10 Feb 2022

Researchers develop new weapon to fight against resistant bacteria

Every day, people die from simple infections even though they have been treated with antibiotics. This is because more and more bacteria have become resistant to the types of antibiotics that doctors can prescribe.

10 Feb 2021

Researchers develop new way of testing bacterial resistance to antibiotics

A new method to analyze a commonly understood route for antibiotic resistance could lead to earlier detection of antibiotic resistant bacteria.

14 Aug 2018

Researchers characterize S. aureus gene involved in virulence and antibiotic resistance

An Institut Pasteur-CNRS research team has characterized a Staphylococcus aureus gene involved in virulence, biofilm formation and resistance to certain antibiotics.

23 Mar 2018

Eczema can increase patients' risk of developing several other health conditions

When a patient is diagnosed with eczema, the diagnosis of another medical condition may not be far behind.

28 Jul 2016

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has licensed commercialisation rights for Ozenoxacin one per cent cream in Canada to Cipher Pharmaceuticals Inc.

8 Jan 2015

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings.

16 Dec 2014

Rhine-Waal students bag first place in research poster competition at European Detergents Conference

Rhine-Waal students Aleksandar Hizman, Sabine Vollmer, Chantal Baumann, Kim Krieger and Lars Frohn, undergraduates in the Quality, Environment, Safety and Hygiene programme of the Faculty of Life Sciences, won first place in a research poster competition at the 10th annual European Detergents Conference, held in conjunction with the SEPAWA Congress in Fulda, Germany.

3 Dec 2014

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.

12 Jun 2014

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

FDA clears Meridian Bioscience’s new illumigene Group A Strep test

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received FDA clearance for a new molecular diagnostic test for Group A Streptococcus on the illumigene platform.

18 Sep 2012

Patients with history of skin infection more likely to develop surgical site infections

Johns Hopkins scientists have engineered cells that behave like AND and OR Boolean logic gates, producing an output based on one or more unique inputs. This feat, published in the May issue of Nature Chemical Biology, could eventually help researchers create computers that use cells as tiny circuits.

30 May 2012

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its lead compound, NVC-422, to prevent urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.

2 Mar 2011

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has been ranked seventh in the biotech industry in Fast Company's annual list of the world's most innovative companies in 2011.

19 Feb 2011

Dermatologists urge athletes to be aware of most common skin infections

Team sports have a long history of fostering cooperation, camaraderie and a healthy competitive spirit among athletes. But the closeness that brings athletes together also can create an environment for a host of contagious skin infections. Now, dermatologists are urging teammates and coaches to be aware of the most common skin conditions caused by bacteria, viruses and fungi that occur in athletes and educating them on how to prevent a widespread outbreak.

5 Feb 2011

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces a successful meeting with the US Food and Drug Administration (FDA) to discuss the Company's clinical development of its Aganocide compound NVC-422, intended for use in the treatment of impetigo.

29 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

12 Nov 2010